Innorna Recognized Among the Best Startups for the 2026 Prix Galien USA Award

Innorna Nominated for the 2026 Prix Galien USA Best Startup Award

On August 13, 2026, Innorna, a biotechnology firm specializing in clinical-stage RNA-based medicines, announced that it has received a prestigious nomination for the 2026 Prix Galien USA Best Startup Award. This nomination highlights the company’s commitment to innovation and its advanced platform for RNA medicines, setting it apart in a competitive health space.

Innorna has excelled in developing its messenger RNA (mRNA) lipid nanoparticle (LNP) platform, which is recognized for moving beyond just vaccines into therapeutic realms. Its most notable product, IN026, represents a groundbreaking mRNA therapy targeting refractory gout. This therapy is designed to substantially lower uric acid levels and has received an Investigational New Drug (IND) approval from the FDA in March 2026. This pivotal milestone expands the horizons of mRNA technologies to treat widespread chronic diseases, marking a significant step in therapeutic innovations.

The Prix Galien is often referred to as the "Nobel Prize of the pharmaceutical industry," and it seeks to honor exceptional achievement in medical innovation that enhances human health. The award winners are determined by panels of distinguished biomedical scientists, industry executives, and Nobel Laureates from across the globe, adding to the prestige associated with this recognition.

Dr. Linxian Li, the founder and CEO of Innorna, expressed his gratitude and pride regarding the nomination. “We are truly honored to be recognized as a finalist for the Prix Galien USA Best Startup. This nomination reflects the significant progress our team has accomplished in advancing our clinical product portfolio, cultivated through years of specialized platform engineering. It also serves as a reminder of our mission to develop RNA-based therapeutics that provide better treatment alternatives for patients worldwide.”

The winners of the 2026 Prix Galien USA Awards will be announced during an awards ceremony scheduled for October 29, 2026, at the American Museum of Natural History in New York. This event promises to spotlight several key players in the biotechnology field, offering valuable exposure for nominees like Innorna.

About Innorna

Innorna is at the forefront of biotechnology, focusing on the development of RNA medicines aimed at improving patient lives globally. With a robust and continually expanding portfolio of intellectual property, the company utilizes a patented and unique platform for RNA delivery and engineering. This includes a well-characterized library of over 6,000 chemically diverse ionizable lipids, as well as advanced LNP delivery systems.

The vertical integration of Innorna’s capabilities—from discovery through to cGMP manufacturing—equips the company with exceptional technical expertise and accelerates development, ensuring efficient capital usage. Innorna is actively developing a strong pipeline of mRNA products aimed at chronic disease therapies, in vivo immunotherapies, and vaccines, reinforcing its commitment to innovation in healthcare. As of now, the firm has successfully raised $150 million to support its endeavors, underscoring significant investor confidence in its vision and potential.

The nomination for the 2026 Prix Galien USA Best Startup Award is a testament to Innorna’s innovative spirit and a promising indicator of its future contributions to the field of biotechnology.